|
|
|
|
|
|
Sponsored by: |
Allegheny General Hospital |
Information provided by: | Allegheny General Hospital |
ClinicalTrials.gov Identifier: | NCT00425126 |
Delayed graft function (DGF) is a major complication following deceased donor renal transplantation. The surgical procedure of harvesting a kidney from a cadaveric donor and implanting the kidney into the recipient inevitably causes some amount of injury. While not always clinically significant, anywhere from 10-50% of transplant patients may develop DGF. Ongoing research in animal models has demonstrated benefit with administration of erythropoietin. We propose to study the effect of Procrit(Epoetin Alfa) on delayed graft function in subjects undergoing kidney transplantation.
Condition | Intervention | Phase |
Delayed Graft Function |
Drug: Epoetin Alfa |
Phase IV |
MedlinePlus related topics: | Kidney Transplantation |
ChemIDplus related topics: | Epoetin alfa Erythropoietin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment |
Official Title: | Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Richard Marcus, MD | 412-359-3319 | rmarcus@wpahs.org |
United States, Pennsylvania | |||||
Allegheny General Hospital | Recruiting | ||||
Pittsburgh, Pennsylvania, United States, 15212 |
Allegheny General Hospital |
Principal Investigator: | Richard J Marcus, MD | Allegheny General Hospital |
Study ID Numbers: | RC-4044 |
First Received: | January 18, 2007 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00425126 |
Health Authority: | United States: Institutional Review Board |
|
|
|